AGENTIX CORP. : Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K)

Item 2.01 Completion or Disposition of Assets.

The information provided in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference.

At the Merger Effective Time, all limited liability company interests of Applied issued and outstanding immediately prior to the Merger Effective Time were automatically cancelled and converted into the right to receive one share of common stock, par value $0.001 per share, of the Company. The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which was filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on July 14, 2021.

On July 14, 2021, Articles of Merger effecting the Merger were filed with the Secretary of State of the State of Nevada.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:



Exhibit   Description
  2.1       Agreement and Plan of Merger (the "Merger Agreement"), dated July 13,
          2021, by and among Agentix Corp., AB Merger LLC, a Nevada limited
          liability company, and Applied Biopharma LLC, a Nevada limited liability
          company. (1)

(1) Incorporated by reference to Current Report on Form 8-K filed with the SEC on July 14, 2021

2

© Edgar Online, source Glimpses